Literature DB >> 2969433

Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor.

J Thiery1, V W Armstrong, J Schleef, C Creutzfeldt, W Creutzfeldt, D Seidel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2969433     DOI： 10.1007/bf01745519

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN： 0023-2173


× No keyword cloud information.
  11 in total

1.  Structural relationship of an apolipoprotein (a) phenotype (570 kDa) to plasminogen: homologous kringle domains are linked by carbohydrate-rich regions.

Authors:  H Kratzin; V W Armstrong; M Niehaus; N Hilschmann; D Seidel
Journal:  Biol Chem Hoppe Seyler       Date:  1987-12

2.  cDNA sequence of human apolipoprotein(a) is homologous to plasminogen.

Authors:  J W McLean; J E Tomlinson; W J Kuang; D L Eaton; E Y Chen; G M Fless; A M Scanu; R M Lawn
Journal:  Nature       Date:  1987 Nov 12-18       Impact factor: 49.962

3.  Plasma lipoproteins: teaching old dogmas new tricks.

Authors:  M S Brown; J L Goldstein
Journal:  Nature       Date:  1987 Nov 12-18       Impact factor: 49.962

4.  Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study.

Authors:  R J Havel; D B Hunninghake; D R Illingworth; R S Lees; E A Stein; J A Tobert; S R Bacon; J A Bolognese; P H Frost; G E Lamkin
Journal:  Ann Intern Med       Date:  1987-11       Impact factor: 25.391

5.  Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment.

Authors:  A Gurakar; J M Hoeg; G Kostner; N M Papadopoulos; H B Brewer
Journal:  Atherosclerosis       Date:  1985-11       Impact factor: 5.162

6.  Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits.

Authors:  P T Ma; G Gil; T C Südhof; D W Bilheimer; J L Goldstein; M S Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

7.  Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). A dose-response study of the effects of cholestyramine in hypercholesterolaemia.

Authors:  B Vessby; G Kostner; H Lithell; J Thomis
Journal:  Atherosclerosis       Date:  1982-07       Impact factor: 5.162

8.  Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia.

Authors:  M J Mol; D W Erkelens; J A Leuven; J A Schouten; A F Stalenhoef
Journal:  Lancet       Date:  1986-10-25       Impact factor: 79.321

9.  Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography.

Authors:  G H Dahlen; J R Guyton; M Attar; J A Farmer; J A Kautz; A M Gotto
Journal:  Circulation       Date:  1986-10       Impact factor: 29.690

10.  The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels.

Authors:  V W Armstrong; P Cremer; E Eberle; A Manke; F Schulze; H Wieland; H Kreuzer; D Seidel
Journal:  Atherosclerosis       Date:  1986-12       Impact factor: 5.162
View more
  20 in total

Review 1.  Lipoprotein (a). Heterogeneity and biological relevance.

Authors:  A M Scanu; G M Fless
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

Review 2.  Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.

Authors:  J P Desager; Y Horsmans
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

3.  Reduction of Lp(a) by different methods of plasma exchange.

Authors:  I Schenck; C Keller; S Hailer; G Wolfram; N Zöllner
Journal:  Klin Wochenschr       Date:  1988-12-15

4.  Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout.

Authors:  S Takahashi; T Yamamoto; Y Moriwaki; Z Tsutsumi; K Higashino
Journal:  Ann Rheum Dis       Date:  1995-02       Impact factor: 19.103

5.  Serum LP(A) levels in randomized healthy men from different European countries.

Authors:  M Cigolini; J C Seidell; M G Zenti; G Bonadonna; L Zambelli; J P Deslypere; F Contaldo; A Cruz; J Charzewska; G Targher
Journal:  Eur J Epidemiol       Date:  1993-09       Impact factor: 8.082

6.  Combined therapy with probucol and pravastatin in hypercholesterolaemia. One year follow-up study.

Authors:  K Saku; B Zhang; K Hirata; Y Okura; H Bai; R Liu; K Arakawa
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  Hormonal regulation of serum Lp (a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma.

Authors:  P Henriksson; B Angelin; L Berglund
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

8.  Apolipoprotein(a) and cardiovascular disease in type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy.

Authors:  F S Nielsen; A I Voldsgaard; M A Gall; P Rossing; E Hommel; P Andersen; J Dyerberg; H H Parving
Journal:  Diabetologia       Date:  1993-05       Impact factor: 10.122

9.  Long-term effect of lovastatin alone and in combination with cholestyramine on lipoprotein (a) level in familial hypercholesterolemic subjects.

Authors:  T P Leren; I Hjermann; O P Foss; P Leren; K Berg
Journal:  Clin Investig       Date:  1992-08

10.  Changes in serum lipoprotein(a) in hyperlipidemic subjects undergoing long-term treatment with lipid-lowering drugs.

Authors:  A S Dobs; M Prasad; A Goldberg; M Guccione; D R Hoover
Journal:  Cardiovasc Drugs Ther       Date:  1995-10       Impact factor: 3.727
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.